1264191-95-8

Basic information

• Product Name: 1-(1-(2-oxo-2H-chromen-3-yl)ethylidene)-2-(4-(4-methoxyphenyl)thiazol-2-yl)hydrazine
• Synonyms: 1-(1-(2-oxo-2H-chromen-3-yl)ethylidene)-2-(4-(4-methoxyphenyl)thiazol-2-yl)hydrazine
• CAS NO: 1264191-95-8
• Molecular Weight: 391.45
• Mol File: 1264191-95-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 1-(1-(2-oxo-2H-chromen-3-yl)ethylidene)-2-(4-(4-methoxyphenyl)thiazol-2-yl)hydrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(1-(2-oxo-2H-chromen-3-yl)ethylidene)-2-(4-(4-methoxyphenyl)thiazol-2-yl)hydrazine(1264191-95-8)
• EPA Substance Registry System: 1-(1-(2-oxo-2H-chromen-3-yl)ethylidene)-2-(4-(4-methoxyphenyl)thiazol-2-yl)hydrazine(1264191-95-8)

Safety Data

• Hazardous Substances Data: 1264191-95-8(Hazardous Substances Data)

Upstream product

• 3949-36-8 3-acetylcoumarin 
• 79-19-6 thiosemicarbazide 
• 2632-13-5 2-Bromo-4'-methoxyacetophenone 
• 52831-78-4 2-(1-(2-oxo-2H-chromen-3-yl)ethylidene)hydrazine-1-carbothioamide 

Relevant articles and documents

A facile one-pot, three-component synthesis of a new series of thiazolyl pyrazole carbaldehydes: In vitro anticancer evaluation, in silico ADME/T, and molecular docking studies

A series of thiazolyl pyrazole carbaldehydes (4a-n) were synthesized by conventional method using thiosemicarbazide, substituted phenacyl bromides, substituted 3-acetylcoumarins, and Vilsmeyer-Hack reagent. Structures of all the synthesized compounds were confirmed by spectral (1H & 13C NMR, FTIR, Mass) and analytical data. The target compounds were screened for their in vitro anticancer activity. From the results, it was found that the compound 4m has shown significant antiproliferative activity against all tested cell-lines. Furthermore, in silico ADME/T profiles were also carried out to set effective lead candidates for the future anticancer drug discovery initiatives. Molecular docking studies were carried out against colchicine binding site of β-tubulin and the results were in concordance with the in vitro anticancer data.